Roche's Actemra shows promise for sJIA in Phase III study
This article was originally published in Scrip
Roche's first-in-class interleukin-6 inhibitor RoActemra (tocilizumab; known as Actemra outside of the EU) improved the signs and symptoms of systemic juvenile idiopathic arthritis (sJIA), full data from the Phase III TENDER study show. There are no approved treatments for sJIA in the US and the EU, but RoActemra was approved for the condition in Japan in 2008.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.